China's food and drug regulator has approved Eli Lilly's Kisunla (donanemab) treatment for early symptomatic Alzheimer's disease, marking the fourth major market to grant approval. This follows approvals in the U.S., Japan, and the UK earlier this year. Donanemab targets beta amyloid, clearing it from the brain and differs from Leqembi in requiring finite dosing once plaques are cleared.
) said on Tuesday evening that China’s food and drug regulator had approved its Kisunla treatment for early symptomatic Alzheimer's disease- the fourth major market to approve the treatment.) Products Administration in China, after being approved in the U.S., Japan, and the UK earlier this year. Kisunla- which is sold under the name donanemab, was approved by the U.S. FDA in July.) Leqembi, which was approved in 2023.
A major point of difference between Donanemab and Leqembi is that the Eli Lilly treatment requires finite dosing, in that treatment can be stopped once the amyloid plaques are cleared from the brain. The treatment is priced much higher in the U.S., at about $32,000 for 12 months of treatment, compared to a $26,500 cost for Leqembi.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
ALZHEIMER's CHINA MEDICATION DONANEMAB ELI LILLY
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trialEli Lilly’s cholesterol pill impressed in a mid-stage trial. Meanwhile, Dexcom invested $75 million in Oura.
Read more »
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, ZepboundEli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Read more »
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, ZepboundEli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Read more »
Oracle, AutoZone and Alaska Air fell premarket; Eli Lilly roseOracle, AutoZone and Alaska Air fell premarket; Eli Lilly rose
Read more »
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, ZepboundEli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Read more »
Eli Lilly: Breakthrough Trial Results Set Stage for Market Growth, Stock GainsStocks Analysis by Michael Lebowitz covering: Eli Lilly and Company, Novo Nordisk A/S. Read Michael Lebowitz's latest article on Investing.com
Read more »